Pharsight

Nicorette generic

Nicorette is a nicotine based drug owned by Glaxosmithkline. It was first authorized for market use on 09 February, 1996. The active ingredient in Nicorette is nicotine polacrilex. Nicorette is available in gum, chewing and buccal dosage forms.

When will Nicorette generic be available?

Nicorette has a total of 3 drug patents. All of these patents are still effective, with none having expired so far. The generic version of Nicorette could potentially be released after the 14 June, 2029. This date corresponds with the expiry date of the last patent 'Nicotine lozenge compositions' with patent number US8501164.

Nicorette uses

Nicorette is used widely in the cessation of smoking. It delivers nicotine to your system through the gum, reducing cravings and withdrawal symptoms associated with quitting smoking. The active ingredient, nicotine polacrilex, is responsible for this effect.

Nicorette patent expiration

Nicorette holds three patents with the last expiring on 14 June, 2029. This suggests that any generics of Nicorette might only become available after this date. Below are the details of the patents:

EPO Oppostions filed on Nicorette

Nicorette dosage

Want to ask something?